

# Critical data-based re-evaluation of minocycline as a putative specific microglia inhibitor

Thomas Möller\*<sup>1,2</sup>, Frédérique Bard<sup>3</sup>, Anindya Bhattacharya<sup>4</sup>, Knut Biber<sup>5,6</sup>, Brian Campbell<sup>1</sup>, Elena Dale<sup>1</sup>, Claudia Eder<sup>7</sup>, Li Gan<sup>8</sup>, Gwenn A. Garden<sup>2</sup>, Zoë A. Hughes<sup>9</sup>, Damien Pearse<sup>10</sup>, Roland G.W. Staal<sup>1</sup>, Faten A. Sayed<sup>8,11</sup>, Paul D. Wes<sup>1</sup>, and Erik Boddeke<sup>6</sup>

<sup>1</sup>Neuroinflammation Disease Biology Unit, Lundbeck Research USA, Paramus, NJ 07652, USA.

<sup>2</sup>Department of Neurology, University of Washington, Seattle WA 98195, USA

<sup>3</sup>Janssen Prevention Center, San Diego, CA

<sup>4</sup>Janssen Research & Development, LLC. Neuroscience Drug Discovery, San Diego, CA 92121 USA

<sup>5</sup>Department of Psychiatry and Psychotherapy, University Hospital Freiburg, 79104 Freiburg, FRG

<sup>6</sup>Department of Neuroscience, University Medical Center Groningen, 9713 Groningen, The Netherlands.

<sup>7</sup>Institute for Infection and Immunity, St. George's - University of London, London SW17 0RE, UK

<sup>8</sup>Gladstone Institute for Neurodegeneration, San Francisco, CA 94158 USA

<sup>9</sup>Neuroscience & Pain Research Unit, Pfizer Global Research Cambridge, MA 02139 USA

<sup>10</sup>University of Miami Miller School of Medicine, Neurological Surgery, Miami, FL 33136, USA

<sup>11</sup>Neuroscience Graduate Program, University of California, San Francisco, San Francisco, CA 94143, USA

Running title: Why minocycline is not a specific microglia inhibitor

Word count:

Abstract: 82

Text: 1992

Bibliography: 2459

Figure Legends: 7

Total:

Figures: 1

Tables: 1

\*Corresponding author:

Thomas Möller

[moeller@uw.edu](mailto:moeller@uw.edu)

Main Points:

- Minocycline is not a specific microglia inhibitor
- Minocycline has *bona fide* effects on neuroinflammation *in vivo*
- Data generated with minocycline are difficult to interpret

Key Words: microglia, minocycline, lack of specificity, inhibitor

## ABSTRACT

Minocycline, a second generation broad-spectrum antibiotic, has been frequently postulated to be a “microglia inhibitor”. A considerable number of publications have used minocycline as a tool and concluded, after achieving a pharmacological effect, that the effect must be due to “inhibition” of microglia. It is, however, unclear how this “inhibition” is achieved at the molecular and cellular level. Here we weigh the evidence whether minocycline is indeed a *bona fide* microglia inhibitor and discuss how data generated with minocycline should be interpreted.

## **Minocycline, a second generation tetracycline antibiotic**

Minocycline is a semi-synthetic, broad-spectrum tetracycline antibiotic. It was first synthesized from natural tetracyclines in 1966 (Redin 1966) and approved by the federal drug administration (FDA) for the US in 1971. The bacteriostatic activity of tetracycline antibiotics (incl. minocycline) results from binding the bacterial 30S ribosomal subunit, blocking the attachment of aminoacyl-tRNA to the ribosome and thus preventing the addition of new amino acids to the nascent peptide chain (Chopra and Roberts 2001). Minocycline has a long serum half life of 11-18 hours, which is 2-3 times longer than the typical water-soluble tetracyclines (Agwuh and MacGowan 2006). Minocycline is the most lipid-soluble of the tetracycline family, affording it the greatest CNS penetrance in the group (Brain-to-serum ratio in dogs: minocycline 2.8; doxycycline 1.3; tetracycline 0.3) (Barza et al. 1975). While this is an obvious advantage for CNS indications, such as Lyme disease, it also is the underlying cause of CNS side effects such as dizziness, vertigo, ataxia and tinnitus (Fanning et al. 1977). These vestibular side effects are more common in women than in men, occurring with a frequency of up to 7/10 (Fanning et al. 1977). Minocycline has other well described peripheral and central side and because of multiple potential safety issues, the FDA added minocycline to its Adverse Event Reporting System (ARES) in 2009 effects (Balestrero et al. 2001; Cohen 2004; Davies and Kersey 1989; Fraser et al. 2012; Golstein et al. 1997; Gordon et al. 1995; Gough et al. 1996; Hanada et al. 2016; Hardman et al. 1996; Healy et al. 2009; Lander 1989; Lefebvre et al. 2007; Matsuura et al. 1992; Porter and Harrison 2003; Schlienger et al. 2000; van Steensel 2004; Weller and Klockgether 1998). That said, minocycline remains a mainstay drug for anti-bacterial therapy and has been taken safely and efficiently by millions of people.

## **Anti-inflammatory effects of tetracycline-based antibiotics**

Early evidence for non-antibiotic properties of tetracycline antibiotics (e.g. tetracycline, doxycycline, minocycline, for structures see Fig.1) surfaced in dermatology and rheumatoid arthritis (Clark 1995; Eady et al. 1993; Galland 1995; Greenwald et al. 1992; Kloppenburg et al. 1996; Miyachi et al. 1986). By early 2016 more than 2850 papers on the anti-inflammatory properties of tetracycline antibiotics were listed in PubMed. The reported mechanisms include inhibition of T-cell activation, inhibition of neutrophil transmigration, inhibition of proinflammatory cytokine release, inhibition of nitric oxide release and augmentation of anti-inflammatory cytokine release (Table 1) (Bernardino et al. 2009; Bostanci et al. 2011; Cazalis et al. 2009; Celerier et al. 1996; Eady et al. 1993; Garrido-Mesa et al. 2013; Greenwald et al. 1992; Jain et al. 2002; Kloppenburg et al. 1996; Kloppenburg et al. 1995; Koistinaho et al. 2004; Milano et al.

1997; Miyachi et al. 1986; Ochsendorf 2010; Pang et al. 2012; Sadarangani et al. 2015; Sapadin and Fleischmajer 2006; Shapira et al. 1996; Toussirof et al. 1997). The list of effects is far from complete and one has to keep in mind that not all properties have been investigated for all tetracyclines. However, there seems to be consensus that the second generation tetracyclines (e.g. doxycycline, minocycline) have improved anti-inflammatory properties (Garrido-Mesa et al. 2013; Leite et al. 2011). In fact, based on the intriguing anti-inflammatory properties of the second generation tetracyclines, efforts are underway to engineer tetracycline-based molecules without antibiotic, but improved anti-inflammatory properties (Cazalis et al., 2009; Monk et al., 2011; Tilakaratne and Soory, 2014).

Coincidentally, tetracyclines are also being used to regulated gene transcription in transgenic animals. In the 1990 the Tet-Off and Tet-On systems have been developed utilizing the Tet repressor DNA binding protein (TetR) from the tetracycline resistance operon of *Escherichia coli* transposon Tn10 (Furth et al. 1994; Gossen and Bujard 1992; Kistner et al. 1996). This system is used to regulate the expression of a target gene that is under transcriptional control of a tetracycline-responsive promoter element (TRE). These systems have found wide adaption for the temporal regulation of gene expression or deletion (Mansuy and Bujard 2000; Sakai 2014; Zhu et al. 2002b). While originally coined the “tetracycline regulated expression system”, most experiments are performed with doxycycline as the Tet-On system responds poorly to tetracycline, but well to doxycycline (Baron and Bujard 2000). If these systems are used to investigate an animal model where the phenotype is associated with an inflammatory component, it might be difficult to separate the the Tet-On/Off effect from the anti-inflammatory properties of doxycycline (See Table 1).

As of early 2016, about 750 papers in PubMed refer to minocycline’s anti-inflammatory effects. Of the three major tetracyclines (i.e. tetracycline, doxycycline, minocycline) minocycline is the best investigated in regards to anti-inflammatory effects (Table 1) (Garrido-Mesa et al. 2013; Ochsendorf 2010). However, while the effects on inflammation and immune cells (e.g. monocytes, macrophages, T-cells, neutrophils) are well described, the actual molecular mechanism by which minocycline exerts these effects are far less understood. Many molecules in pro- and anti-inflammatory signal transduction cascades have been suggested, such NF- $\kappa$ B, LOX-1, LPS-induced TNF- $\alpha$  factor (LITAF), Nur77, p38 MAPK, PI3K/Ak, PKC, IRF-1 and the inflammasome (Dunston et al. 2011; Kauppinen et al. 2014; Nikodemova et al. 2007; Pang et al. 2012). However, while the evidence for anti-inflammatory activity of minocycline is overwhelming, the molecular target(s) of minocycline mediating these effects still remain elusive.

## **Minocycline employed as a putative microglia inhibitor**

The keywords “microglia AND minocycline” return over 500 hits from PubMed in early 2016. There is a large body of data showing anti-inflammatory effects of minocycline on microglial (patho)physiology *in vitro* as well as *in vivo*. Similar to effects on peripheral immune cells, typical effects reported include reduction in cytokine, prostaglandin and nitric oxide release, reduced proliferation and reduced staining for “activation” markers such as CD11b, MHC-II or Iba-1 (El-Shimy et al. 2015; Hanlon et al. 2016; Hou et al. 2016; Nikodemova et al. 2007; Papa et al. 2016; Scholz et al. 2015; Silva Bastos et al. 2011; Tikka et al. 2001; Tikka and Koistinaho 2001) and reviewed in (Zemke and Majid 2004). Based on the available data for minocycline as a CNS penetrant anti-inflammatory these data are not surprising. However, several publications have called minocycline a “selective microglia inhibitor” and have drawn conclusions on microglia involvement in animal models of disease solely based on the effects of minocycline (Cui et al. 2008; Huang et al. 2014; Kobayashi et al. 2013; Ledebuer et al. 2005; Mika et al. 2007; Osikowicz et al. 2009; Raghavendra et al. 2003). It should be self-evident, that minocycline is not selective for microglia, but affects peripheral immune cells as well. Therefore, an unequivocal attribution of the pharmacological effects to microglia, especially in the *in vivo* experiments is not possible. Furthermore, it is unclear what is being “inhibited”. Microglia “activation”? In turn, are only “activated” microglia effected by minocycline? What about microglia “surveying” the tissue? It is becoming clear that microglia exist in different phenotypes (Biber et al. 2014; Hanisch 2013). Consequently, which phenotype(s) are “inhibited” by minocycline with which outcome? The term “microglia inhibition” seems as vaguely-defined as the term “microglia activation”.

## **Minocycline effects on astrocytes, oligodendrocytes and neurons**

In addition to its broad effects on immune cells, minocycline has been shown to have multiple effects on astrocytes, oligodendrocytes and neurons *in vitro* as well as *in vivo*. For example, minocycline (and doxycycline) reduces the release of the pro-inflammatory cytokines TNF- $\alpha$ , IL-6, and IL-8 from cultured rhesus monkey astrocytes (Bernardino et al. 2009). Minocycline reduced the number of hippocampal GFAP<sup>+</sup> cells in LPS challenged mice and in the mutant SOD1 model of amyotrophic lateral sclerosis (Hou et al. 2016; Keller et al. 2011). Minocycline also protected oligodendrocytes and oligodendrocyte precursors against hypoxic and traumatic injury *in vitro* and *in vivo* (Scheuer et al. 2015; Schmitz et al. 2012; Stirling et al. 2004; Yune et al. 2007). There is a plethora of reports of neuroprotection and direct effects on neurons by tetracyclines including minocycline (reviewed in (Domercq and Matute 2004).

However, the effects of minocycline are not always positive. Several publications report neurotoxic effects of minocycline (Arnoux et al. 2014; Diguët et al. 2004a; Diguët et al. 2004b; Diguët et al. 2003; Tsuji et al. 2004; Yang et al. 2003). Of course, in the absence of proof positive, one has to acknowledge that the effects on astrocytes, oligodendrocytes and neurons, especially *in vivo* could be indirect. By the same token, however, the reported effects attributed to “microglia inhibition” could be indirect as well. For example, improved neuronal outcomes, would most likely be accompanied by less “activation” of surrounding microglia. Because of the uncertainty which cell(s) or networks are affected by minocycline, it only seems prudent to interpret minocycline *in vivo* data in regards to the cell type affected with the utmost caution.

## **Minocycline in clinical trials targeting microglia**

Based on encouraging data on minocycline’s broad anti-inflammatory effects, over 150 clinical trials have been registered at [clinicaltrials.gov](http://clinicaltrials.gov) (early 2016) for the use of minocycline as standalone or adjunctive therapy in indications ranging from atrial fibrillation, to Angelman Syndrome and schizophrenia (US-National-Institutes-of-Health). In the last decade minocycline has received considerable attention for CNS applications reviewed (Garrido-Mesa et al. 2013; Zemke and Majid 2004). Of the currently registered trials, ten specifically refer to a “microglia activation” mechanism in diseases like hypertension, opioid-induced hyperalgesia, and schizophrenia. Registration in [clinicaltrials.gov](http://clinicaltrials.gov) is voluntary and other pilot trials for minocycline have been reported for Parkinson’s disease, Huntington’s disease and Multiple sclerosis (Bonelli et al. 2004; Chen et al. 2011; Huntington Study Group 2010; Investigators 2006; Thomas et al. 2004; Zabad et al. 2007; Zhang et al. 2008). While many of the targeted diseases have a *bona fide* microglia/neuroinflammation component (Garden and Möller 2006; Möller 2010) it is not always obvious which effect of minocycline (anti-inflammatory, neuroprotective, etc.) the trials are aiming to leverage.

There is at least one CNS disease where minocycline is contraindicated. Based on positive effects in rodent models of amyotrophic lateral sclerosis (ALS) (Kriz et al. 2002; Van Den Bosch et al. 2002; Zhu et al. 2002a), and promising phase I/II clinical trials (Gordon et al. 2004; Pontieri et al. 2005), a randomized Phase III clinical trial was run in ALS patients. Unexpectedly, disease progression in ALS patients given minocycline was faster than the control group (Gordon et al. 2007). This effect, however, was not dose-dependent as patients on low and high doses fared equally unfavorable compared to controls (Gordon et al. 2007). This negative effect was later replicated in a mouse model of ALS where, in contrast to prior studies, minocycline treatment was started after disease onset (Keller et al. 2011).

## **Minocycline is not a selective microglia inhibitor**

The anti-inflammatory activity of minocycline (and other tetracyclines) is well documented and undisputed. However, whether this activity can be solely attributed to a “microglia inhibitory effect” seems rather unlikely. The data presented here should make it clear that any activity attributed to minocycline has multiple potential cellular targets and a still unknown set of molecular targets. As such, data generated with minocycline need to be interpreted with caution. In the worst case, there might be experiments where the reported “improvements” in animal models are in fact due to the primary activity of the agent - i.e. antibacterial activity - in animals exposed to (unintentional) bacterial challenges. In the best case, the well documented, “anti-inflammatory” or “neuroprotective” activity of minocycline, coupled with its high CNS penetrance, might exert the effect “somewhere” in the CNS. Regardless of the actual activity and target, this might be good news for patients in the long run. When minocycline, a drug with a well-documented record in the clinic, holds up in human trials, it could enable a quick entry into clinical practice for the benefit of patients. Nevertheless, the learnings from the ALS clinical trial should give the most endeavoring mind pause. In the preclinical area, data generated with minocycline, should not be misconstrued as a proof of microglial involvement. Instead, such preclinical data should be seen as document of minocycline’s undisputed plethora of anti-inflammatory, anti-apoptotic and neuroprotective properties.

## **Conflict of interest**

TM, ED, RGWS, PDW were full time employees of Lundbeck Research USA.

FB, AB are full time employees of Janssen Pharmaceutica.

ZAH is a full time employee of Pfizer.

## **Acknowledgements**

We thank Dario Doller for help with Figure 1.



## REFERENCES

- Agwuh KN, MacGowan A. 2006. Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylicyclines. *J Antimicrob Chemother* 58:256-65.
- Arnoux I, Hoshiko M, Sanz Diez A, Audinat E. 2014. Paradoxical effects of minocycline in the developing mouse somatosensory cortex. *Glia* 62:399-410.
- Balestrero S, Ciambellotti A, Parodi A, Rebora A. 2001. Minocycline-induced lupus-like syndrome. *Int J Dermatol* 40:474-5.
- Baron U, Bujard H. 2000. Tet repressor-based system for regulated gene expression in eukaryotic cells: principles and advances. *Methods Enzymol* 327:401-21.
- Barza M, Brown RB, Shanks C, Gamble C, Weinstein L. 1975. Relation between lipophilicity and pharmacological behavior of minocycline, doxycycline, tetracycline, and oxytetracycline in dogs. *Antimicrob Agents Chemother* 8:713-20.
- Bernardino AL, Kaushal D, Philipp MT. 2009. The antibiotics doxycycline and minocycline inhibit the inflammatory responses to the Lyme disease spirochete *Borrelia burgdorferi*. *J Infect Dis* 199:1379-88.
- Biber K, Owens T, Boddeke E. 2014. What is microglia neurotoxicity (Not)? *Glia* 62:841-54.
- Bonelli RM, Hodl AK, Hofmann P, Kapfhammer HP. 2004. Neuroprotection in Huntington's disease: a 2-year study on minocycline. *Int Clin Psychopharmacol* 19:337-42.
- Bostanci N, Akgul B, Tsakanika V, Allaker RP, Hughes FJ, McKay IJ. 2011. Effects of low-dose doxycycline on cytokine secretion in human monocytes stimulated with *Aggregatibacter actinomycetemcomitans*. *Cytokine* 56:656-61.
- Cazalis J, Tanabe S, Gagnon G, Sorsa T, Grenier D. 2009. Tetracyclines and chemically modified tetracycline-3 (CMT-3) modulate cytokine secretion by lipopolysaccharide-stimulated whole blood. *Inflammation* 32:130-7.
- Celerier P, Litoux P, Dreno B. 1996. In vitro modulation of epidermal inflammatory cytokines (IL-1 alpha, IL-6, TNF alpha) by minocycline. *Arch Dermatol Res* 288:411-4.
- Chen X, Ma X, Jiang Y, Pi R, Liu Y, Ma L. 2011. The prospects of minocycline in multiple sclerosis. *J Neuroimmunol* 235:1-8.
- Chopra I, Roberts M. 2001. Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance. *Microbiol Mol Biol Rev* 65:232-60 ; second page, table of contents.
- Clark HW. 1995. Minocycline and rheumatoid arthritis revisited. *Ann Intern Med* 123:393.
- Cohen PR. 2004. Medication-associated depersonalization symptoms: report of transient depersonalization symptoms induced by minocycline. *South Med J* 97:70-3.
- Cui Y, Liao XX, Liu W, Guo RX, Wu ZZ, Zhao CM, Chen PX, Feng JQ. 2008. A novel role of minocycline: attenuating morphine antinociceptive tolerance by inhibition of p38 MAPK in the activated spinal microglia. *Brain Behav Immun* 22:114-23.
- Davies MG, Kersey PJ. 1989. Acute hepatitis and exfoliative dermatitis associated with minocycline. *BMJ* 298:1523-4.
- Diguet E, Fernagut PO, Wei X, Du Y, Rouland R, Gross C, Bezard E, Tison F. 2004a. Deleterious effects of minocycline in animal models of Parkinson's disease and Huntington's disease. *Eur J Neurosci* 19:3266-76.
- Diguet E, Gross CE, Tison F, Bezard E. 2004b. Rise and fall of minocycline in neuroprotection: need to promote publication of negative results. *Exp Neurol* 189:1-4.

- Diguet E, Rouland R, Tison F. 2003. Minocycline is not beneficial in a phenotypic mouse model of Huntington's disease. *Ann Neurol* 54:841-2.
- Domercq M, Matute C. 2004. Neuroprotection by tetracyclines. *Trends Pharmacol Sci* 25:609-12.
- Dunston CR, Griffiths HR, Lambert PA, Staddon S, Vernallis AB. 2011. Proteomic analysis of the anti-inflammatory action of minocycline. *Proteomics* 11:42-51.
- Eady EA, Ingham E, Walters CE, Cove JH, Cunliffe WJ. 1993. Modulation of comedonal levels of interleukin-1 in acne patients treated with tetracyclines. *J Invest Dermatol* 101:86-91.
- El-Shimy IA, Heikal OA, Hamdi N. 2015. Minocycline attenuates Abeta oligomers-induced pro-inflammatory phenotype in primary microglia while enhancing Abeta fibrils phagocytosis. *Neurosci Lett* 609:36-41.
- Fanning WL, Gump DW, Sofferan RA. 1977. Side effects of minocycline: a double-blind study. *Antimicrob Agents Chemother* 11:712-7.
- Fraser CL, Biousse V, Newman NJ. 2012. Minocycline-induced fulminant intracranial hypertension. *Arch Neurol* 69:1067-70.
- Furth PA, St Onge L, Boger H, Gruss P, Gossen M, Kistner A, Bujard H, Hennighausen L. 1994. Temporal control of gene expression in transgenic mice by a tetracycline-responsive promoter. *Proc Natl Acad Sci U S A* 91:9302-6.
- Galland L. 1995. Minocycline and rheumatoid arthritis revisited. *Ann Intern Med* 123:392-3.
- Garden GA, Möller T. 2006. Microglia biology in health and disease. *J Neuroimmune Pharmacol* 1:127-37.
- Garrido-Mesa N, Zarzuelo A, Galvez J. 2013. Minocycline: far beyond an antibiotic. *Br J Pharmacol* 169:337-52.
- Golstein PE, Deviere J, Cremer M. 1997. Acute hepatitis and drug-related lupus induced by minocycline treatment. *Am J Gastroenterol* 92:143-6.
- Gordon PH, Moore DH, Gelinis DF, Qualls C, Meister ME, Werner J, Mendoza M, Mass J, Kushner G, Miller RG. 2004. Placebo-controlled phase I/II studies of minocycline in amyotrophic lateral sclerosis. *Neurology* 62:1845-7.
- Gordon PH, Moore DH, Miller RG, Florence JM, Verheijde JL, Doorish C, Hilton JF, Spitalny GM, MacArthur RB, Mitsumoto H and others. 2007. Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. *Lancet Neurol* 6:1045-53.
- Gordon PM, White MI, Herriot R, Martin JC, Reid DM. 1995. Minocycline-associated lupus erythematosus. *Br J Dermatol* 132:120-1.
- Gossen M, Bujard H. 1992. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. *Proc Natl Acad Sci U S A* 89:5547-51.
- Gough A, Chapman S, Wagstaff K, Emery P, Elias E. 1996. Minocycline induced autoimmune hepatitis and systemic lupus erythematosus-like syndrome. *BMJ* 312:169-72.
- Greenwald RA, Moak SA, Ramamurthy NS, Golub LM. 1992. Tetracyclines suppress matrix metalloproteinase activity in adjuvant arthritis and in combination with flurbiprofen, ameliorate bone damage. *J Rheumatol* 19:927-38.
- Hanada Y, Berbari EF, Steckelberg JM. 2016. Minocycline-Induced Cutaneous Hyperpigmentation in an Orthopedic Patient Population. *Open Forum Infect Dis* 3:ofv107.
- Hanisch UK. 2013. Functional diversity of microglia - how heterogeneous are they to begin with? *Front Cell Neurosci* 7:65.
- Hanlon LA, Huh JW, Raghupathi R. 2016. Minocycline Transiently Reduces Microglia/Macrophage Activation but Exacerbates Cognitive Deficits Following Repetitive Traumatic Brain Injury in the Neonatal Rat. *J Neuropathol Exp Neurol*.
- Hardman CM, Leonard JN, Thomas HC, Goldin R. 1996. Minocycline and hepatitis. *Clin Exp Dermatol* 21:244-5.

- Healy J, Alexander B, Eapen C, Roberts-Thomson IC. 2009. Minocycline-induced autoimmune hepatitis. *Intern Med J* 39:487-8.
- Hou Y, Xie G, Liu X, Li G, Jia C, Xu J, Wang B. 2016. Minocycline protects against lipopolysaccharide-induced cognitive impairment in mice. *Psychopharmacology (Berl)* 233:905-16.
- Huang CY, Chen YL, Li AH, Lu JC, Wang HL. 2014. Minocycline, a microglial inhibitor, blocks spinal CCL2-induced heat hyperalgesia and augmentation of glutamatergic transmission in substantia gelatinosa neurons. *J Neuroinflammation* 11:7.
- Huntington Study Group DI. 2010. A futility study of minocycline in Huntington's disease. *Mov Disord* 25:2219-24.
- Investigators NN-P. 2006. A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. *Neurology* 66:664-71.
- Jain A, Sangal L, Basal E, Kaushal GP, Agarwal SK. 2002. Anti-inflammatory effects of erythromycin and tetracycline on *Propionibacterium acnes* induced production of chemotactic factors and reactive oxygen species by human neutrophils. *Dermatol Online J* 8:2.
- Kauppinen A, Salminen A, Kaarniranta K. 2014. Inflammation as a target of minocycline: special interest in the regulation of inflammasome signaling. *Inflammasome* 1:2-14.
- Keller AF, Gravel M, Kriz J. 2011. Treatment with minocycline after disease onset alters astrocyte reactivity and increases microgliosis in SOD1 mutant mice. *Exp Neurol* 228:69-79.
- Kistner A, Gossen M, Zimmermann F, Jerecic J, Ullmer C, Lubbert H, Bujard H. 1996. Doxycycline-mediated quantitative and tissue-specific control of gene expression in transgenic mice. *Proc Natl Acad Sci U S A* 93:10933-8.
- Kloppenborg M, Dijkmans BA, Verweij CL, Breedveld FC. 1996. Inflammatory and immunological parameters of disease activity in rheumatoid arthritis patients treated with minocycline. *Immunopharmacology* 31:163-9.
- Kloppenborg M, Verweij CL, Miltenburg AM, Verhoeven AJ, Daha MR, Dijkmans BA, Breedveld FC. 1995. The influence of tetracyclines on T cell activation. *Clin Exp Immunol* 102:635-41.
- Kobayashi K, Imagama S, Ohgomori T, Hirano K, Uchimura K, Sakamoto K, Hirakawa A, Takeuchi H, Suzumura A, Ishiguro N and others. 2013. Minocycline selectively inhibits M1 polarization of microglia. *Cell Death Dis* 4:e525.
- Koistinaho J, Yrjanheikki J, Kauppinen T, Koistinaho M. 2004. Tetracycline derivatives as anti-inflammatory agents and potential agents in stroke treatment. *Ernst Schering Res Found Workshop*:101-15.
- Kriz J, Nguyen MD, Julien JP. 2002. Minocycline slows disease progression in a mouse model of amyotrophic lateral sclerosis. *Neurobiol Dis* 10:268-78.
- Lander CM. 1989. Minocycline-induced benign intracranial hypertension. *Clin Exp Neurol* 26:161-7.
- Ledeboer A, Sloane EM, Milligan ED, Frank MG, Mahony JH, Maier SF, Watkins LR. 2005. Minocycline attenuates mechanical allodynia and proinflammatory cytokine expression in rat models of pain facilitation. *Pain* 115:71-83.
- Lefebvre N, Forestier E, Farhi D, Mahsa MZ, Remy V, Lesens O, Christmann D, Hansmann Y. 2007. Minocycline-induced hypersensitivity syndrome presenting with meningitis and brain edema: a case report. *J Med Case Rep* 1:22.
- Leite LM, Carvalho AG, Ferreira PL, Pessoa IX, Goncalves DO, Lopes Ade A, Goes JG, Alves VC, Leal LK, Brito GA and others. 2011. Anti-inflammatory properties of doxycycline and minocycline in experimental models: an in vivo and in vitro comparative study. *Inflammopharmacology* 19:99-110.
- Mansuy IM, Bujard H. 2000. Tetracycline-regulated gene expression in the brain. *Curr Opin Neurobiol* 10:593-6.
- Matsuura T, Shimizu Y, Fujimoto H, Miyazaki T, Kano S. 1992. Minocycline-related lupus. *Lancet* 340:1553.

- Mika J, Osikowicz M, Makuch W, Przewlocka B. 2007. Minocycline and pentoxifylline attenuate allodynia and hyperalgesia and potentiate the effects of morphine in rat and mouse models of neuropathic pain. *Eur J Pharmacol* 560:142-9.
- Milano S, Arcoleo F, D'Agostino P, Cillari E. 1997. Intraperitoneal injection of tetracyclines protects mice from lethal endotoxemia downregulating inducible nitric oxide synthase in various organs and cytokine and nitrate secretion in blood. *Antimicrob Agents Chemother* 41:117-21.
- Miyachi Y, Yoshioka A, Imamura S, Niwa Y. 1986. Effect of antibiotics on the generation of reactive oxygen species. *J Invest Dermatol* 86:449-53.
- Möller T. 2010. Neuroinflammation in Huntington's disease. *J Neural Transm (Vienna)* 117:1001-8.
- Nikodemova M, Watters JJ, Jackson SJ, Yang SK, Duncan ID. 2007. Minocycline down-regulates MHC II expression in microglia and macrophages through inhibition of IRF-1 and protein kinase C (PKC)alpha/betaII. *J Biol Chem* 282:15208-16.
- Ochsendorf F. 2010. Minocycline in acne vulgaris: benefits and risks. *Am J Clin Dermatol* 11:327-41.
- Osikowicz M, Skup M, Mika J, Makuch W, Czarkowska-Bauch J, Przewlocka B. 2009. Glial inhibitors influence the mRNA and protein levels of mGlu2/3, 5 and 7 receptors and potentiate the analgesic effects of their ligands in a mouse model of neuropathic pain. *Pain* 147:175-86.
- Pang T, Wang J, Benicky J, Saavedra JM. 2012. Minocycline ameliorates LPS-induced inflammation in human monocytes by novel mechanisms including LOX-1, Nur77 and LITAF inhibition. *Biochim Biophys Acta* 1820:503-10.
- Papa S, Caron I, Erba E, Panini N, De Paola M, Mariani A, Colombo C, Ferrari R, Pozzer D, Zanier ER and others. 2016. Early modulation of pro-inflammatory microglia by minocycline loaded nanoparticles confers long lasting protection after spinal cord injury. *Biomaterials* 75:13-24.
- Pontieri FE, Ricci A, Pellicano C, Benincasa D, Buttarelli FR. 2005. Minocycline in amyotrophic lateral sclerosis: a pilot study. *Neurol Sci* 26:285-7.
- Porter D, Harrison A. 2003. Minocycline-induced lupus: a case series. *N Z Med J* 116:U384.
- Raghavendra V, Tanga F, DeLeo JA. 2003. Inhibition of microglial activation attenuates the development but not existing hypersensitivity in a rat model of neuropathy. *J Pharmacol Exp Ther* 306:624-30.
- Redin GS. 1966. Antibacterial activity in mice of minocycline, a new tetracycline. *Antimicrob Agents Chemother (Bethesda)* 6:371-6.
- Sadarangani SP, Estes LL, Steckelberg JM. 2015. Non-anti-infective effects of antimicrobials and their clinical applications: a review. *Mayo Clin Proc* 90:109-27.
- Sakai N. 2014. Principles for the use of in vivo transgene techniques: overview and an introductory practical guide for the selection of tetracycline-controlled transgenic mice. *Methods Mol Biol* 1142:33-40.
- Sapadin AN, Fleischmajer R. 2006. Tetracyclines: nonantibiotic properties and their clinical implications. *J Am Acad Dermatol* 54:258-65.
- Scheuer T, Brockmoller V, Blanco Knowlton M, Weitkamp JH, Ruhwedel T, Mueller S, Endesfelder S, Buhner C, Schmitz T. 2015. Oligodendroglial maldevelopment in the cerebellum after postnatal hyperoxia and its prevention by minocycline. *Glia* 63:1825-39.
- Schlienger RG, Bircher AJ, Meier CR. 2000. Minocycline-induced lupus. A systematic review. *Dermatology* 200:223-31.
- Schmitz T, Endesfelder S, Chew LJ, Zaak I, Buhner C. 2012. Minocycline protects oligodendroglial precursor cells against injury caused by oxygen-glucose deprivation. *J Neurosci Res* 90:933-44.
- Scholz R, Sobotka M, Caramoy A, Stempf T, Moehle C, Langmann T. 2015. Minocycline counter-regulates pro-inflammatory microglia responses in the retina and protects from degeneration. *J Neuroinflammation* 12:209.
- Shapira L, Soskolne WA, Houri Y, Barak V, Halabi A, Stabholz A. 1996. Protection against endotoxic shock and lipopolysaccharide-induced local inflammation by tetracycline: correlation with inhibition of cytokine secretion. *Infect Immun* 64:825-8.

- Silva Bastos LF, Pinheiro de Oliveira AC, Magnus Schlachetzki JC, Fiebich BL. 2011. Minocycline reduces prostaglandin E synthase expression and 8-isoprostane formation in LPS-activated primary rat microglia. *Immunopharmacol Immunotoxicol* 33:576-80.
- Stirling DP, Khodarahmi K, Liu J, McPhail LT, McBride CB, Steeves JD, Ramer MS, Tetzlaff W. 2004. Minocycline treatment reduces delayed oligodendrocyte death, attenuates axonal dieback, and improves functional outcome after spinal cord injury. *J Neurosci* 24:2182-90.
- Thomas M, Ashizawa T, Jankovic J. 2004. Minocycline in Huntington's disease: a pilot study. *Mov Disord* 19:692-5.
- Tikka T, Fiebich BL, Goldsteins G, Keinanen R, Koistinaho J. 2001. Minocycline, a tetracycline derivative, is neuroprotective against excitotoxicity by inhibiting activation and proliferation of microglia. *J Neurosci* 21:2580-8.
- Tikka TM, Koistinaho JE. 2001. Minocycline provides neuroprotection against N-methyl-D-aspartate neurotoxicity by inhibiting microglia. *J Immunol* 166:7527-33.
- Toussiroit E, Despau J, Wendling D. 1997. Do minocycline and other tetracyclines have a place in rheumatology? *Rev Rhum Engl Ed* 64:474-80.
- Tsuji M, Wilson MA, Lange MS, Johnston MV. 2004. Minocycline worsens hypoxic-ischemic brain injury in a neonatal mouse model. *Exp Neurol* 189:58-65.
- US-National-Institutes-of-Health. <https://clinicaltrials.gov/ct2/results?term=minocycline&Search=Search>.
- Van Den Bosch L, Tilkin P, Lemmens G, Robberecht W. 2002. Minocycline delays disease onset and mortality in a transgenic model of ALS. *Neuroreport* 13:1067-70.
- van Steensel MA. 2004. Why minocycline can cause systemic lupus - a hypothesis and suggestions for therapeutic interventions based on it. *Med Hypotheses* 63:31-4.
- Weller M, Klockgether T. 1998. Minocycline-induced benign intracranial hypertension. *J Neurol* 245:55.
- Yang L, Sugama S, Chirichigno JW, Gregorio J, Lorenzl S, Shin DH, Browne SE, Shimizu Y, Joh TH, Beal MF and others. 2003. Minocycline enhances MPTP toxicity to dopaminergic neurons. *J Neurosci Res* 74:278-85.
- Yune TY, Lee JY, Jung GY, Kim SJ, Jiang MH, Kim YC, Oh YJ, Markelonis GJ, Oh TH. 2007. Minocycline alleviates death of oligodendrocytes by inhibiting pro-nerve growth factor production in microglia after spinal cord injury. *J Neurosci* 27:7751-61.
- Zabad RK, Metz LM, Todoruk TR, Zhang Y, Mitchell JR, Yeung M, Patry DG, Bell RB, Yong VW. 2007. The clinical response to minocycline in multiple sclerosis is accompanied by beneficial immune changes: a pilot study. *Mult Scler* 13:517-26.
- Zemke D, Majid A. 2004. The potential of minocycline for neuroprotection in human neurologic disease. *Clin Neuropharmacol* 27:293-8.
- Zhang Y, Metz LM, Yong VW, Bell RB, Yeung M, Patry DG, Mitchell JR. 2008. Pilot study of minocycline in relapsing-remitting multiple sclerosis. *Can J Neurol Sci* 35:185-91.
- Zhu S, Stavrovskaya IG, Drozda M, Kim BY, Ona V, Li M, Sarang S, Liu AS, Hartley DM, Wu DC and others. 2002a. Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. *Nature* 417:74-8.
- Zhu Z, Zheng T, Lee CG, Homer RJ, Elias JA. 2002b. Tetracycline-controlled transcriptional regulation systems: advances and application in transgenic animal modeling. *Semin Cell Dev Biol* 13:121-8.

## Tables:

**Table 1:** Anti-inflammatory effects of selected tetracyclines. + indicates published data supporting anti-inflammatory effect of a given drug. CAVE: Absence of proof however, is not proof of absence of the effect. (Bernardino et al. 2009; Bostanci et al. 2011; Cazalis et al. 2009; Celerier et al. 1996; Eady et al. 1993; Garrido-Mesa et al. 2013; Greenwald et al. 1992; Jain et al. 2002; Kloppenburg et al. 1996; Kloppenburg et al. 1995; Koistinaho et al. 2004; Milano et al. 1997; Miyachi et al. 1986; Ochsendorf 2010; Pang et al. 2012; Sadarangani et al. 2015; Sapadin and Fleischmajer 2006; Shapira et al. 1996; Toussirot et al. 1997).

## Figures

**Figure 1:** Chemical structures of tetracycline, doxycycline and minocycline.